Univasc (Moexipril) - Drug Information, Research, Clinical Trials, News

Rx drug information, pharmaceutical research, clinical trials, news, and more

Drugs by Name

Drugs by Condition

Drugs by Category

Alerts

Univasc Rx

FDA Alerts Summary Description Indications and Dosage Warnings and Precautions Side Effects and Adverse Reactions Drug Interactions, Overdosage and Contraindications Clinical Pharmacology Other Rx Information Active Ingredients Adverse Event Reports

Univasc News

News in Media Published Studies Curr't Clinical Trials

Nutrilib.com A comprihensive source of nutritional information

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, univasc® should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

UNIVASC SUMMARY

univasc® (moexipril hydrochloride), the hydrochloride salt of moexipril, has the empirical formula C₂₇H₃₄N₂O₇ ·HCl and a molecular weight of 535. It is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat.

univasc® is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics.

In using univasc®, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that univasc® does not have a similar risk (see WARNINGS).

In considering use of univasc®, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS, Angioedema).
See all Univasc indications & dosage >>